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Abstract 
Objectives: Sterol regulatory element-binding proteins (SREBP) genes are crucial in lipid biosynthesis 
and cardiovascular homeostasis. Their expression in epicardial adipose tissue (EAT) and their influence 
in the development of coronary artery disease (CAD) and type-2 diabetes mellitus remain to be 
determined. The aim of our study was to evaluate the expression of SREBP genes in EAT in patients with 
CAD according to diabetes status and its association with clinical and biochemical data. 
Methods: SREBP-1 and SREBP-2 mRNA expression levels were measured in EAT from 49 patients 
with CAD (26 with diabetes) and 23 controls without CAD or diabetes.  
Results: Both SREBPs mRNA expression were significantly higher in patients with CAD and diabetes 
(p<0.001) and were identified as independent cardiovascular risk factor for coronary artery disease in 
patients with type-2 diabetes (SREBP-1: OR 1.7, 95%CI 1.1-2.5, p=0.02; SREBP-2: OR 1.6, 95%CI 1.2-3, 
p=0.02) and were independently associated with the presence of multivessel CAD, left main and 
anterior descending artery stenosis, and higher total and LDL cholesterol levels, and lower HDL 
cholesterol levels, in patients with CAD and diabetes.  
Conclusions: SREBP genes are expressed in EAT and were higher in CAD patients with diabetes than 
those patients without CAD or diabetes. SREBP expression was associated as cardiovascular risk factor 
for the severity of CAD and the poor lipid control. In this preliminary study we suggest the importance 
of EAT in the lipid metabolism and cardiovascular homeostasis for coronary atherosclerosis of patients 
with diabetes and highlight a future novel therapeutic target. 
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The biosynthesis of cholesterol, fatty acid, and 
triglyceride is regulated by a family of major 
transcription factors, called Sterol regulatory 
element-binding proteins (SREBPs) [1]. They control 
the expression of crucial genes involved in lipogenesis 
and lipid uptake. Due to SREBPs play a vital role in 
synthesizing of lipids, its dysregulation may be 
intimately associated with type-2 diabetes mellitus 
(DM2), obesity and cardiovascular diseases [2,3].  
In humans there are two SREBP genes, SREBP-1 
and SREBP-2. SREBP-1 is more associated with the 
control of genes involved in fatty acid metabolism and 
SREBP-2 is closely associated with cholesterol 
biosynthesis and metabolism. SREBP-1 is most 
abundant in the liver and adrenal gland, whereas 
SREBP-2 is ubiquitously expressed [4]. 
Epicardial adipose tissue (EAT) represents a 
visceral fat depot located between the myocardium 
and the inner layer of visceral pericardium [5]. EAT 
participates in the energy homeostasis of the heart 
and the vessels. In fact, the functional EAT has been 
proposed to play a protector role over the 
myocardium or coronary arteries. However, EAT 
dysfunction has been implicated in the development 
and progression of coronary artery disease (CAD), 
mainly in patients with DM2, involving a more 
aggressive course and greater morbidity and 
mortality than in patients without DM2 [6].  
EAT has not been fully characterized and has 
gained significant attention in recent years [5]. 
Actually, the expression of SREBP genes in EAT and 
the role of this tissue in the lipid biosynthesis and 
metabolism, and subsequently, in coronary 
atherosclerosis, has not been widely described. The 
aim of our study was to evaluate the expression of 
SREBP-1 and SREBP-2 in EAT in patients with CAD, 
stablishing the difference between patients with and 
without DM2. We hypothesized that SREBP genes 
would be expressed in EAT and would be altered 
according to diabetes status, playing an important 
role in the cardiovascular system of CAD patients. We 
also assessed the possible association between SREBP 
expression and clinical and biochemical data in 
patients of our cohort.  
Methods 
Patients 
We included a total of 49 patients who 
underwent Coronary Artery Bypass Surgery (CAD 
group) and 23 patients who underwent aortic and/or 
mitral valve replacement (Control group). The CAD 
group was divided into two groups: those with DM2 
(n=26) (CAD-DM2 group) and those without DM2 
(n=23) (CAD-NDM2).  
The CAD was defined by the presence of greater 
than or equal to 50% luminal diameter stenosis in at 
least one major epicardial artery by coronary 
angiogram. Multivessel disease was defined as the 
presence of this stenosis in two or more major 
epicardial arteries. Stenosis of one major epicardial 
artery was considered as single vessel disease. 
Patients of the Control group had chronic valvular 
heart disease, without CAD or DM2.  
Exclusion criteria were acute inflammatory 
disease, severe infective disease and/or cancer, and 
women who were taking hormone replacement.  
All patients gave written informed consent, and 
the study protocol was approved by the local Clinical 
Research Ethics Committee and carried out in 
accordance with the Declaration of Helsinki. 
Biological material 
Human EAT biopsy samples (average 0.2 to 0.5g) 
were taken near the proximal right coronary artery, 
approximately 1 hour after anesthesia. All the tissues 
were frozen immediately in liquid nitrogen and 
stored at -80ºC for RNA isolation.  
Blood assays 
On the morning of surgery, peripheral venous 
blood was drawn into pyrogen-free tubes with or 
without EDTA as an anticoagulant. For serum, the 
tubes were left at room temperature for 20 min and 
then centrifuged at 1500 g for 10 min at 4ºC. Fasting 
glucose, glycated hemoglobin (HbA1c), total 
cholesterol, low-density lipoprotein (LDL), high- 
density lipoprotein (HDL), triglycerides, creatinine, 
uric acid, glutamic-oxolacetic transaminase (GOT), 
glutamate-piruvate transaminase (GPT), gamma- 
glutamyl transferase (GGT), C-reactive protein (CRP), 
calcium, sodium and potassium were measured in a 
Dimension autoanalyzer (Dade Behring Inc., 
Deerfield, IL) by enzymatic methods (Randox 
Laboratories, Ldt., UK) in the hospital laboratory.  
RNA Isolation and TaqMan Real-Time Reverse 
Transcription–Polymerase Chain Reaction 
Adipose tissue samples were minced in TriZol 
reagent (Invitrogen) and homogenized completely on 
ice. Total RNA was extracted by chloroform and 
purified through RNeasy minicolumns. After 
on-column DNase treatment, RNA was eluted with 
Rnase-free water. Total RNA was quantified with a 
spectrophotometer (Nanodrop N-100, Thermo 
Scientific), and all samples had a 260/280 nm 
absorbance ratio ≥1.8. Reverse transcriptions were 
performed using 1 µg of total RNA with Transcriptor 
First Strand cDNA Synthesis Kit (Roche) and random 




hexamers in 20 µl reactions. The gene expression 
levels in the adipose tissue were determined by real 
time quantitative polymerase chain reaction (PCR) 
using a predesigned and validated Taqman 
primer/probe sets. Real-time PCR amplifications 
were performed on 96-well plates in reaction buffer 
containing Taqman Universal PCR Master Mix (No 
AmpErase UNG, Applied Biosystems, USA), 150 nM 
Taqman probe, 900 nM primers, and 22.5 ng cDNA. 
PCR reaction conditions were 48°C for 30 minutes, 
95°C for 10 minutes, followed by 40 cycles of 95°C for 
15 seconds and 60°C for 1 minute using an ABI 7500 
Fast Detection System (Applied Biosystems). Data 
were obtained as Ct values according to the 
manufacturer’s guidelines (the cycle number at which 
logarithmic PCR plots cross a calculated threshold 
line) and were used to determine ΔCt values (ΔCt = Ct 
of the target gene minus Ct of the housekeeping 
gene). Cyclophilin A transcripts were amplified in the 
same reaction to normalize for variance in input RNA. 
mRNA expression levels relative to cyclophilin A 
were calculated by the 2-ΔCt method. All tests were 
performed in duplicate. A negative control, RNA 
amplification without previous retrotranscription, 
was done to test for possible genomic DNA 
contamination. 
Statistical analysis 
Normality of continuous variables was checked 
by means of the Kolmogorov-Smirnov test. 
Continuous variables are summarized as mean ± SD. 
Discrete variables are presented as frequencies and 
percentages. Comparison between the results of the 
different groups was made with the analysis of 
variance (ANOVA) and chi-square test for continuous 
and categorical data, respectively. The post hoc 
analysis was done with the Bonferroni test. Logistic 
regression models were used in order to identify 
independent factors (Odds ratio [OR]; 95% 
Confidence Interval) for CAD in patients with DM2 
associated with SREBP-1 and SREBP-2 expression, as 
well as to control for confounding factors. Statistical 
analyses were performed with SPSS for Windows 
version 15 (SPSS Inc. Chicago, IL, USA). Values were 
considered to be statistically significant when P<0.05. 
Results 
General characteristics of the patients 
Among the 49 patients with CAD in our study 
cohort, 53.1% (n=26) had DM2 (CAD-DM2 group). 
Table 1 lists clinical and biochemical differences 
between patients with CAD according to diabetes 
status and Control group. Patients with CAD and 
DM2 were more likely to have hypertension and 
dyslipidemia, higher levels of glucose, HbA1c, total 
and LDL cholesterol, triglycerides and C-reactive 
protein, and lower HDL-cholesterol levels than those 
without DM2 and controls. Angiotensin converting 
enzyme inhibitors/Angiotensin II receptor blockers 
were more often used in CAD-DM2 and Control 
group, and Aspirin and Statins in CAD patients with 
and without DM2.  
Table 1. Clinical and biochemical characteristics of patients with coronary artery disease according to diabetes status and control group. 
Variables N (%) CAD-DM2 (n=26) CAD-NDM2 (n=23) p value* CONTROL (n=23) p value** p value*** p value 
Age, years 64.4 ± 10.2 65.1 ± 10.8 0.225 62 ± 10 0.201 0.187 0.204 
Male gender 20 (76.9%) 17 (73.9%) 0.245 15 (65.2%) 0.09 0.100 0.166 
Smoking 18 (69.2%) 16 (69.6%) 0.344 12 (52.2%) 0.06 0.07 0.07 
Body mass index, kg/m2 29 ± 6 28.4 ± 5 0.102 27.8 ± 4.1 0.101 0.124 0.113 
Obesity 14 (53.8%) 11 (47.8%) 0.127 10 (43.4%) 0.08 0.114 0.144 
Hypertension 23 (88.5%) 18 (78.3%) 0.203 17 (74%) 0.333 0.533 0.293 
Dyslipidemia 21 (80.8%) 18 (78.3%) 0.121 16 (69.6%) 0.08 0.09 0.09 
Cerebrovascular disease 2 (7.7%) 1 (4.3%) 0.141 2 (8.7%) 0.119 0.09 0.186 
Left ventricular ejection fraction, % 55 ± 6 53 ± 6 0.288 52 ± 6 0.288 0.601 0.257 
Left ventricular ejection fraction ≤40% 5 (19.2%) 4 (17.4%) 0.199 4 (17.4%) 0.201 0.249 0.209 
Medications   
Aspirin 23 (88.5%) 20 (87%) 0.185 8 (34.8%) 0.01 0.01 0.02 
Statins 20 (76.9%) 17 (73.9%) 0.108 15 (65.2%) 0.06 0.09 0.09 
ACEI/ARB 23 (88.5%) 16 (69.6) 0.04 19 (82.6%) 0.107 0.04 0.03 
Beta-blocker 21 (80.8%) 19 (82.6) 0.201 18 (78.3%) 0.113 0.101 0.155 
Biochemical data   
Glucose, mg/dL 151 ± 38 108 ± 33 0.01 103 ± 29 0.01 0.217 0.02 
HbA1c, % 7.9 ± 1 5.8 ± 0.5 0.01 5.5 ± 0.5 0.01 0.188 0.01 
Total cholesterol, mg/dL 189 ± 31 159 ± 28 0.02 160 ± 30 0.02 0.201 0.01 
LDL cholesterol, mg/dL 122 ± 26 100 ± 20 0.04 103 ± 21 0.04 0.199 0.04 
HDL cholesterol, mg/dL 30 ± 6 49 ± 9 0.03 44 ± 9 0.02 0.214 0.03 
Triglycerides, mg/dL 203 ± 60 157 ± 42 0.03 148 ± 40 0.03 0.108 0.03 
Creatinine, mg/dL 1.14 ± 0.51 1.17 ± 0.76 0.244 1 ± 0.32 0.277 0.199 0.281 
Uric acid, mg/dL 5.4 ± 2 6.1 ± 2.1 0.141 6.2 ± 2.2 0.219 0.109 0.207 
GOT, IU/L 32.8 ± 21 29.3 ± 27 0.218 34 ± 28 0.111 0.221 0.281 
GPT, IU/L 40.1 ± 35 37 ±29 0.109 42.7 ± 34 0.241 0.247 0.194 




GGT, IU/L 60 ± 33 58.3 ± 31 0.285 67.7 ± 32 0.189 0.112 0.188 
CRP, mg/dL 51.6 ± 41 31.3 ± 30 0.03 19.2 ± 22 0.01 0.02 0.02 
Calcium, mg/dL 8.5 ± 0.7 8.6 ± 0.7 0.334 8.9 ± 0.8 0.147 0.218 0.222 
Potassium, mmol/L 4.3 ± 0.5 4 ± 0.5 0.311 4.1 ± 0.5 0.213 0.201 0.218 
Sodium, mmol/L 138 ± 3.6 137 ± 3 0.321 139 ± 3.7 0.244 0.299 0.274 
Values are shown as mean ± SD and frequencies (percentages). Comparison between the results of the different groups was made with the analysis of variance (ANOVA) and chi-square 
test for continuous and categorical data, respectively. The post hoc analysis was done with the Bonferroni test. Values were considered to be statistically significant when P<0.05. 
p value: overall comparison for all groups. p value*: CAD-DM2 vs CAD-NDM2 comparison. p value** CAD-DM2 vs CONTROL comparison. p value*** CAD-NDM2 vs CONTROL 
comparison. 
ACEI: Angiotensin Converting Enzyme Inhibitor; ARB: Antiotensin II Receptro Blocker; CAD-DM2: Coronary Artery Disease-Type2-Diabetes Mellitus; CAD-NDM2: Coronary Artery 
Disease-Non Type2-Diabetes Mellitus; CRP: C-Reactive Protein; GGT: Gamma-Glutamyl Transferase; GOT: Glutamic-Oxolacetic Transaminase; GPT: Glutamate-Piruvate Transaminase; 
Hb1ac: glycated hemoglobin; HDL: High-Density Lipoprotein; IU/L: international units/liter; kg/m2: kilogram/square metre; LDL: Low-Density Lipoprotein; mg/dL: 
milligram/deciliter; mmol/L: milimol/liter.  
 
 









Multivessel coronary disease 20 (76.9%) 14 (61%) 0.02 
>50% stenosis left main artery 17 (65.4%) 11 (48%) 0.01 
>50% stenosis anterior descending artery 24 (92.3%) 17 (74%) 0.01 
>50% stenosis circumflex artery 19 (73%) 14 (60.9%) 0.02 
>50% stenosis right coronary artery 20 (76.9%) 15 (65.2%) 0.02 
Values are shown as frequencies (percentages). Comparison between the results of the 
different groups was made with chi-square test. Values were considered to be statistically 
significant when P<0.05. 
CAD-DM2: Coronary Artery Disease-Type2-Diabetes Mellitus; CAD-NDM2: Coronary 
Artery Disease-Non Type2-Diabetes Mellitus. 
 
 
Patients of CAD-DM2 group were more likely to 
present multivessel coronary disease and major 
coronary stenosis (Table 2). 
SREBP mRNA expression in EAT and 
comparison between CAD-DM2, CAD-NDM2 
and Control group  
SREBP-1 and SREBP-2 mRNA in EAT were 
significantly higher in patients with CAD and DM2 
compared with CAD-NDM2 (p<0.001) and control 
patients (p<0.001). No SREBP expression differences 
were found between CAD-NDM2 and Control group 
(Figure 1).  
Association between SREBP mRNA 
expression in EAT and biochemical and clinical 
variables according to diabetes status 
Cardiovascular risk factors, such as the presence 
of hypertension and dyslipidemia; biochemical 
parameters, such as glucose, Hb1ac, triglycerides, 
total, LDL and HDL cholesterol; and SREBP-1 and 
SREBP-2 mRNA expression, were identified as 
independent factors for CAD in patients with DM2. 
These results are presented in Table 3. The coefficient 
of determination for this regression model was 0.66. 
In addition, both SREBP-1 and SREBP-2 expression 
were independently associated with the presence of 
multivessel coronary disease, left main artery and 
anterior descending artery stenosis, and higher 
triglycerides, total and LDL cholesterol levels, and 
lower HDL cholesterol levels, in patients with CAD 
and DM2 when compared with patients without DM2 
and controls (Table 4). The coefficient of 
determinations for this model was 0.60. Other clinical 







Figure 1. SREBP-1 (A) and SREBP-2 (B) mRNA expression in EAT comparison 
between groups. CAD: coronary artery disease; DM2: type-2 diabetes mellitus; 








Table 3. Factors for coronary artery disease in patients with 
type-2 diabetes mellitus. 
Variable OR (95% CI) p value B coefficient 
Hypertension 2.3 (1.5-4.1) 0.02 0.541 
Dyslipidemia 3.4 (1.7-5.4) <0.01 0.688 
Glucose, mg/dL 4.4 (1.8-5.8) 0.002 0.718 
Hb1ac, % 4.7 (1.8-6.2) <0.001 0.722 
Total cholesterol, mg/dL 3 (1.3-4.9) 0.02 0.587 
LDL cholesterol, mg/dL 2.6 (1.7-4.6) 0.02 0.581 
HDL cholesterol, mg/dL 2.8 (1.4-5) 0.02 -0.499 
Triglycerides, mg/dL 1.9 (1.1-3.5) 0.03 0.551 
SREBP-1 expression, RU 1.7 (1.1-2.5) 0.02 0.518 
SREBP-2 expression, RU 1.6 (1.2-3) 0.02 0.509 
OR (95% CI) and B coefficient are shown.  
Logistic regression analysis for CAD in patients with DM2. Values were considered to be 
statistically significant when P<0.05. 
95% CI: 95% Confidence Interval; Hb1ac: glycated hemoglobin; HDL: High-Density 
Lipoprotein; LDL: Low-Density Lipoprotein; mg/dL: milligram/deciliter; OR: Odds 
Ratio; RU: Relative Units, SREBP: Sterol Regulatory Expression Binding Protein 
 
Table 4. Factors associated with SREBP-1 and SREBP-2 
expression in patients with coronary artery disease and diabetes 
mellitus. 
 OR (95% CI) p value B coefficient 
SREBP-1 expression, RU 
Multivessel coronary disease 1.6 (1.2-3.8) 0.03 0.487 
Left main artery stenosis 1.3 (1.1-3.4) 0.04 0.458 
Anterior descending artery stenosis 1.3 (1.1-3.8) 0.04 0.438 
Total cholesterol, mg/dL 1.8 (1.2-4.7) 0.03 0.517 
LDL cholesterol, mg/dL 1.6 (1.2-3.6) 0.03 0.521 
HDL cholesterol, mg/dL 1.8 (1.3-4.2) 0.03 -0.499 
Triglycerides, mg/dL 2.8 (1.2-4.5) 0.02 0.561 
SREBP-2 expression, RU 
Multivessel coronary disease 1.3 (1.1-3.4) 0.04 0.431 
Left main artery stenosis 1.2 (1.1-3.5) 0.04 0.437 
Anterior descending artery stenosis 1.3 (1.1-3.6) 0.04 0.444 
Total cholesterol, mg/dL 2.1 (1.3-4.6) <0.01 0.576 
LDL cholesterol, mg/dL 2.6 (1.5-4.9) <0.01 0.601 
HDL cholesterol, mg/dL 2.5 (1.3-4.7) <0.01 -0.576 
Triglycerides, mg/dL 1.4 (1.1-4.6) 0.04 0.461 
OR (95% CI) and B coefficient are shown.  
Logistic regression analysis for SREBP expression in patients with coronary artery disease 
and type2-diabetes mellitus when compared with patients without type2-diabetes mellitus 
and control group. Values were considered to be statistically significant when P<0.05. 
95% CI: 95% Confidence Interval; HDL: High-Density Lipoprotein; LDL: Low-Density 
Lipoprotein; mg/dL: milligram/deciliter; OR: Odds Ratio; RU: Relative Units, SREBP: 




Our study found that SREBP genes are expressed 
in EAT and this expression was significantly higher in 
patients with CAD and DM2. Hypertension, 
dyslipidemia (high triglycerides, total and 
LDL-cholesterol and low HDL cholesterol levels), 
diabetes status (high fasting glucose and Hb1ac 
levels) and SREBP-1 and SREBP-2 mRNA levels were 
associated as cardiovascular risk factor for CAD in 
patients with DM2. Moreover, SREBP expression in 
EAT was independently associated with the severity 
of CAD (presence of multivessel coronary disease, 
and left main artery and anterior descending artery 
stenosis) and poor lipid control (high levels 
triglycerides, total and LDL cholesterol and low HDL 
cholesterol) in patients with DM2.  
These findings are important because the 
expression of SREBP genes had not been previously 
describe in EAT. This study is also important because 
it adds to the relatively limited number of studies that 
have explored the role of this tissue in the lipid 
metabolism, and subsequently, in coronary 
atherosclerosis and cardiovascular disease. In 
addition, this study is unique focused on SREBPs 
expression, crucial genes involved in lipogenesis, 
adipocyte development and cholesterol homeostasis, 
in patients with CAD separated by DM status and 
associated with clinical and biochemical variables.  
Several studies have shown that EAT is 
associated with the development and progression of 
coronary atherosclerosis, mainly through a 
dysbalance of pro/anti-inflammatory adipokines 
production in pathological conditions, as diabetes 
status, speculating about the cardiovascular 
implication of EAT in the DM2 [6-8]. Even, EAT has 
been proposed to participate in the heart energy 
homeostasis [9-11] and, an increase volume of this 
tissue has been demonstrated to be correlated with the 
extent and severity of CAD [8,11,12]. However, a 
functional EAT would play a protector role over the 
myocardium or coronary arteries in healthy humans 
[13].  
Although studies have shown that the 
dysregulation of lipid homeostasis is closely 
associated with DM2 and cardiovascular disease, the 
molecular mechanism and regulation of lipid 
homeostasis is extremely complicated and poorly 
understood. Additionally, a lot of genes and different 
types of tissues involved in this process still remain to 
be discovered [14,15].  
As our results, prior studies have investigated 
the association between the expression of SREBP and 
other genes in different tissues, mainly in liver and 
adipose tissue, and cardiovascular diseases [16-8]. 
SREBPs overexpression has been implicated with 
insulin resistance, carbohydrate and lipid metabolism, 
and has been incriminated in the development of 
human metabolic physiopathology such as obesity, 
DM2, atherosclerosis, increased fatty acid secretion, 
and metabolic syndrome [19-21]. Even, in an extensive 
study performed by Marfella et al [22], was evidenced 
a significant correlation between myocardium SREBP 
expression and myocyte lipid accumulation in 
patients with metabolic syndrome what might 
contribute to heart dysfunction. Similarly to previous 
reports, in the present study, lipid parameters were 
associated with the expression of SREBPs, 
contributing to the high cardiovascular risk, although 
this expression was explored in different tissue.  




It is well known that CAD is the result of 
complex interactions among genetic, metabolic, and 
environmental risk factors. As regulators of 
cholesterol biosynthesis, SREBPs have been proven to 
be associated with CAD, helping in dissecting the 
molecular pathophysiology of CAD. In our study, in 
accordance with the results obtained in other studies 
[23-5], we found association between SREBPs 
expression and extent of coronary lesions. In this line, 
Karasawa et al [26] also showed that the 
overexpression of SREBP accelerated aortic atheroma 
formation and Friedlander et al [17] found an 
association between SREBP and the risk of myocardial 
infarction in among men. Another study, published 
by Robinet et al [27], related SREBP with early-stage 
carotid atherosclerosis in subjects with a risk of 
cardiovascular event but without detectable change in 
plasma lipid levels. So, these findings support a role 
of SREBPs in the development of cardiovascular 
disease.  
Given the role of SREBPs as regulators of 
essential lipid homeostasis, their expression in 
different tissues but specifically in EAT and their 
clinical implication should be deeply characterized as 
an important first step for future studies. In addition, 
the knowledge in this field could have therapeutic 
implications. Regulation of SREBP overexpression 
could be a promising way of treating cardiovascular 
diseases, specialty in patients with CAD and DM2.  
This preliminary study is limited by the small 
number of recruited patients and because our data are 
from a single hospital. In addition, only small EAT 
biopsy samples were taken, being insufficient for a 
proteins determination. However, our study 
preserves its validity because it benefits from a 
well-designed study protocol and has been carried 
out using well-stablished methods. The hypothesis 
that EAT SREBPs expression was involved in CAD in 
patients with DM2 as a cardiovascular risk factor and 
its association with clinical variables and lipid 
parameters would need to be confirmed in further 
research.  
Conclusions  
SREBP-1 and SREBP-2 genes are expressed in 
EAT. This expression was significantly higher in CAD 
patients with DM2 than in those without DM2, and it 
was associated as cardiovascular risk factor for the 
severity of CAD and the poor lipid control. These 
preliminary findings suggest the importance of EAT 
and the SREBP expression in this tissue for the 
cardiovascular homeostasis, and subsequently, for 
coronary atherosclerosis of patients with DM2 and 
highlight a future novel therapeutic target.  
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